Supplementary Materials

Supplementary Material for:

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Bing Z. Carter,* Po Yee Mak, Hong Mu, Hongsheng Zhou, Duncan H. Mak, Wendy Schober, Joel D. Leverson, Bin Zhang, Ravi Bhatia, Xuelin Huang, Jorge Cortes, Hagop Kantarjian, Marina Konopleva, Michael Andreeff*

*Corresponding author. Email: bicarter{at}mdanderson.org (B.Z.C.); mandreef{at}mdanderson.org (M.A.)

Published 7 September 2016, Sci. Transl. Med. 8, 355ra117 (2016)
DOI: 10.1126/scitranslmed.aag1180

This PDF file includes:

  • Fig. S1. Characteristics of Scl-tTa–BCR-ABL transgenic mice.
  • Fig. S2. Expression of proapoptotic Bcl-2 mRNAs in BM cells of Tet-off/on CML mice and in vitro treatment of mouse BM cells.
  • Fig. S3. Enumeration of BM and spleen GFPβˆ’LSK cells in each group after treatment.
  • Fig. S4. Targeting of BCL-2 and BCR-ABL in bulk, CD34+38βˆ’, and CD34+38+ leukemia cells from TKI-resistant BC CML patients.
  • Fig. S5. Targeting of BCL-2 and BCR-ABL with TKIs in bulk, CD34+38βˆ’, and CD34+38+ leukemia cells from TKI-resistant BC CML patients.
  • Fig. S6. Targeting of BCL-2 and BCR-ABL in proliferating and quiescent CD34+ leukemia cells from TKI-resistant BC CML patients.
  • Table S1. Primers used for real-time PCR.
  • Table S2. Antibody panel for CyTOF analysis.
  • Table S3. Data values for Fig. 1C.
  • Table S4. Data values for Fig. 2B.
  • Table S5. Data values for Fig. 2C.
  • Table S6. Data values for Fig. 3A.
  • Table S7. Data values for Fig. 3B.
  • Table S8. Data values for Fig. 4A.
  • Table S9. Data values for Fig. 5A.
  • Table S10. Data values for Fig. 5B.
  • Table S11. Data values for Fig. 5D.
  • Table S12. Data values for Fig. 6B.
  • Table S13. Data values for Fig. 6C.

[Download PDF]